Last reviewed · How we verify
GSK2197870A
GSK2197870A is a S1P1 receptor modulator Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development for Multiple sclerosis. Also known as: GSK Biologicals' combined diphtheria, tetanus, acellular pertussis, polio.
GSK2197870A is a small molecule that targets the S1P1 receptor.
GSK2197870A is a small molecule that targets the S1P1 receptor. Used for Multiple sclerosis.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable. -
Big-pharma sponsor
+3.0pp
GlaxoSmithKline is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | GSK2197870A |
|---|---|
| Also known as | GSK Biologicals' combined diphtheria, tetanus, acellular pertussis, polio, HiB and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine. |
| Sponsor | GlaxoSmithKline |
| Drug class | S1P1 receptor modulator |
| Target | S1P1 |
| Modality | Biologic |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 2 |
Mechanism of action
S1P1 is a sphingosine-1-phosphate receptor that plays a role in lymphocyte trafficking and immune response. By targeting this receptor, GSK2197870A aims to modulate the immune system and potentially treat autoimmune diseases.
Approved indications
- Multiple sclerosis
Common side effects
- Headache
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK2197870A CI brief — competitive landscape report
- GSK2197870A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK2197870A
What is GSK2197870A?
How does GSK2197870A work?
What is GSK2197870A used for?
Who makes GSK2197870A?
Is GSK2197870A also known as anything else?
What drug class is GSK2197870A in?
What development phase is GSK2197870A in?
What are the side effects of GSK2197870A?
What does GSK2197870A target?
Related
- Drug class: All S1P1 receptor modulator drugs
- Target: All drugs targeting S1P1
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Autoimmune diseases
- Indication: Drugs for Multiple sclerosis
- Also known as: GSK Biologicals' combined diphtheria, tetanus, acellular pertussis, polio, HiB and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing